Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01444131|
Recruitment Status : Completed
First Posted : September 30, 2011
Last Update Posted : March 26, 2014
|Condition or disease||Intervention/treatment||Phase|
|Tobacco Dependence||Drug: Varenicline, Nicotine Patch Drug: Varenicline and Placebo Patch||Phase 2|
This is a phase-II multicenter study involving 438 smokers, to be conducted at 7 sites in South Africa, over 6 months. In a randomized 1:1 allocation varenicline tartrate 1 mg twice daily, given in an incremental dosage for the first week before target quit date (TQD), will be compared to varenicline tartrate in the same dose combined with a 15mg nicotine patch. The nicotine patch (active and placebo) will be provided by McNeil. The patch will be given 2 weeks prior TQD. Treatment duration from TQD is 12 weeks with varenicline being tapered off during week 13.
A total of 12 clinic visits and 1 telephonic contact is planned for the 6-month study duration. The main efficacy outcome will be the 4-week continuous abstinence rate during the last four weeks of treatment, i.e. weeks 9 - 12. Efficacy assessments will be based on a Nicotine Use Inventory and measurements of end-expiratory exhaled carbon monoxide. Safety assessments will be based on adverse events evaluation, with special attention being given to the occurrence of nausea during the pretreatment period, as well as neuro-psychiatric symptoms such as depression or suicidal ideation. Participants will not be subjected to any invasive procedures.
This protocol is based on current evidence and two further abstracts presented at the European Respiratory Society Conference in Vienna, September 2009, that a combination of varenicline tartrate and nicotine replacement therapy indicate superior efficacy in cessation rate, but also an excellent good safety profile.
This study relates to the area of pharmacotherapy of smoking cessation, and will answer a frequently asked question. Importantly, several leading pulmonologists with experience in smoking cessation in South Africa have expressed their keen interest to participate in this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||446 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A 26-Week Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation|
|Study Start Date :||April 2011|
|Actual Primary Completion Date :||April 2013|
|Actual Study Completion Date :||June 2013|
Placebo Comparator: Varenicline and Placebo Patch
Varenicline and Nicotine Patch (placebo)
Drug: Varenicline and Placebo Patch
placebo nicotine patches added to varenicline.
Active Comparator: Varenicline and Nicotine Patch
Varenicline and Nicotine Patch 15mg
Drug: Varenicline, Nicotine Patch
active nicotine patches added to varenicline.
- continuous abstinence (CAR) from weeks 9 to 12 of treatment [ Time Frame: 3 months ]The primary endpoint is the 4-week continuous abstincence rate for week 9 - 12 of treatment, i.e. the proportion of patients who are able to maintain complete abstinence from cigarette smoking and other nicotine use, with end-expiratory exhaled carbon monoxide (CO) measurements 10 ppm or less, for the planned last 4 weeks of treatment.
- CAR from weeks 9 to 24 [ Time Frame: 6 months ]The secondary endpoint is the 4-week continuous abstincence rate for week 9 - 24 of treatment, i.e. the proportion of patients who are able to maintain complete abstinence from cigarette smoking and other nicotine use, with end-expiratory exhaled carbon monoxide (CO) measurements 10 ppm or less, for the planned last 4 weeks of treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01444131
|Respiratory Research Unit|
|Cape Town, Western Cape, South Africa, 7505|
|Cape Town, Western Cape, South Africa, 7700|
|UCT Lung Institute|
|Cape Town, Western Cape, South Africa, 8000|
|Dr JA O'Brien|
|Cape Town, Western Cape, South Africa, 8001|
|Dr AHH Brüning|
|Gatesville / Cape Town, Western Cape, South Africa, 7764|
|Dr MS Abdool-Gaffar|
|Amanzimtoti, South Africa, 4126|
|Dr C Smith|
|Sandton, South Africa, 2010|
|Principal Investigator:||Elvis M Irusen, MBChB, FCP, PhD||University of Stellenbosch|